Medistim ASA announced that they are expanding their market coverage in China by establishing a direct sales office, opening today. This move is part of the company's ongoing commitment to providing exceptional service to customers as well as fulfilling the company's global growth strategy. More than 60,000 coronary bypass procedures are performed in China annually and the number is expected to continue to grow high single digit in the years to come.

Today, about 70% of these procedures are supported by Medistim's equipment, which is installed in all the nation's top 10 cardiac surgical centers. The company is well positioned to continue its growth by further expanding the local distributor network and building on the ongoing conversion from devices with Transit Time Flow Measurement (TTFM) technology only, to devices combining TTFM and High-Frequency Ultrasound (HFUS). In addition, a large market within Vascular and Transplant surgery provides opportunities for further growth.